Polymorphisms of p21 and p27 jointly contribute to an earlier age at diagnosis of pancreatic cancer

Cancer Letters

Volumn 272, Issue 1, 2008, Pages 32-39

  Chen, Jinyun ^a   Killary, Ann M ^a,b   Sen, Subrata ^a,b   Amos, Christopher I ^a,b   Evans, Douglas B ^a   Abbruzzese, James L ^a   Frazier, Marsha L ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Age of diagnosis; p21; p27; Pancreatic cancer; Polymorphisms

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN P21; PROTEIN P27;

ADULT; AGE; AGED; ARTICLE; CELL CYCLE ARREST; EARLY DIAGNOSIS; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; P21 GENE; P27 GENE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FAMILY; WILD TYPE;

ADENOCARCINOMA; AGE OF ONSET; AGED; CONTINENTAL POPULATION GROUPS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA PRIMERS; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROPORTIONAL HAZARDS MODELS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 53949083067     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.06.022     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
2. Bardeesy N., and DePinho R.A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2 (2002) 897-909
3. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol. 13 (2003) 65-70
4. Gartel A.L. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk. Res. 29 (2005) 1237-1238
5. Schor E., da Silva I.D., Sato H., Baracat E.C., Girao M.J., and de Freitas V. P27(Kip1) is down-regulated in the endometrium of women with endometriosis. Fertil. Steril. (2008)
6. Chedid M., Michieli P., Lengel C., Huppi K., and Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 9 (1994) 3021-3024
7. Cave H., Martin E., Devaux I., and Grandchamp B. Identification of a polymorphism in the coding region of the p27Kip1 gene. Ann. Genet. 38 (1995) 108
8. Chen J., Li D., Wei C., Sen S., Killary A.M., Amos C.I., et al. Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin. Cancer Res. 13 (2007) 3100-3104
9. Harada K., and Ogden G.R. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. 36 (2000) 3-7
10. Popanda O., Edler L., Waas P., Schattenberg T., Butkiewicz D., Muley T., et al. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55 (2007) 25-34
11. Li G., Liu Z., Sturgis E.M., Shi Q., Chamberlain R.M., Spitz M.R., et al. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 26 (2005) 1596-1602
12. Kibel A.S., Suarez B.K., Belani J., Oh J., Webster R., Brophy-Ebbers M., et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 63 (2003) 2033-2036
13. Keshava C., Frye B.L., Wolff M.S., McCanlies E.C., and Weston A. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 127-130
14. Roh J.W., Kim J.W., Park N.H., Song Y.S., Park I.A., Park S.Y., et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol. Oncol. 93 (2004) 499-505
15. Xi Y.G., Ding K.Y., Su X.L., Chen D.F., You W.C., Shen Y., et al. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 25 (2004) 2201-2206
16. Su L., Liu G., Zhou W., Xu L.L., Miller D.P., Park S., et al. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 174-175
17. Shih C.M., Lin P.T., Wang H.C., Huang W.C., and Wang Y.C. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J. Cancer Res. 91 (2000) 9-15
18. Ma H., Jin G., Hu Z., Zhai X., Chen W., Wang S., et al. Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women. Int. J. Cancer 119 (2006) 2173-2178
19. Li G., Sturgis E.M., Wang L.E., Chamberlain R.M., Spitz M.R., El-Naggar A.K., et al. Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clin. Cancer Res. 10 (2004) 3996-4002
20. Chang B.L., Zheng S.L., Isaacs S.D., Wiley K.E., Turner A., Li G., et al. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res. 64 (2004) 1997-1999
21. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
22. Huppi K., Siwarski D., Dosik J., Michieli P., Chedid M., Reed S., et al. Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). Oncogene 9 (1994) 3017-3020
23. Mousses S., Ozcelik H., Lee P.D., Malkin D., Bull S.B., and Andrulis I.L. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum. Mol. Genet. 4 (1995) 1089-1092
24. Tomoda K., Kubota Y., and Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398 (1999) 160-165